chrisvoncsefalvay/vaers-outcomes huggingface dataset:
ABOUT 2-3 WEEKS AFTER RECIEVING THE SHOT, I WAS FEELING LIKE MY LEFT LEG/FOOT WAS ASLEEP AND FEELING VERY HEAVY.  FIRST WEEK IT WOULD COME AND GO, DIDN'T THINK MUCH OF IT, BUT THAN IT CONTINUED AND NEVER STOPPED WHICH NOW LEADS ME TO HAVE DROP FOOT IN MY LEFT FOOT.  I WAS SENT TO SEE IF IT WAS A BLOOD CLOT WHICH WAS DETERMAINED IT WASN'T, WHICH THAN LEFT ME TO SEE A NEURLOGIST AND THAN TO A NEURSURGEON AND NOW ONTO A ORTHO DOCTOR.  I HAVE HAD A NERVE TEST AND LOTS OF XRAYS AND MRI'S.  I AM NOW ISSUED A ORTHOSIS ANKLE FOOT BOOT TO HELP WITH MY DROP FOOT.  BEEN GOING ON SINCE END OF MARCH APRIL AND I STILL HAVE NO DIRECT ANSWERS.  I KEEP BRINING UP I HAD THE COVID TEST, BUT IT GETS PUSHED ASIDE.
VACCINE WAS MIXED WITH 0.7 OF STERILE WATER AND 0.3 ML SHOT WAS GIVEN. NO ISSUES AT THIS TIME
Small pox vaccine put on PT's right shoulder and lymph nodes on his right side have become inflamed from his right acute bone down to the main site has become painful and turned red.
Pt received HPV and MCv4 on L arm, hep A R arm. On 9/24/13 developed swelling, redness and tenderness on L arm. Seen on 9/26/13 - Rocephin IM given for possible cellulitis. Rocephin given again 9/27/13. Phone call 9/30/13 swelling resolved. No redness or tenderness. Returned to school.
about 12 hours after the vaccination I became feverish, (high of 101.6), Body aches, Headache, vomiting, loose stools, chills and nausea.  It lasted approx. 24-36 hours. The first injection gave me no side effect what so ever.  Please note, as unpleasant as this was I will be getting a 3rd "booster" in January.
Patient developed rash on upper chest and felt as if it was hard to breathe. SOLU MEDROL 125mg IVP given by doctor along with 2 tabs of CLARINEX.
87-year-old female with a PMH of COPD-O2 dependent, CAD, HTN, HLD and skin cancer who presents for increasing lethargy. He also says there is at COVID-19 outbreak and they have been quarantined. According to records she was tested on Tuesday which was negative. Also according to son she had COVID-19 pneumonia and was hospitalized for about a month in April 2020.  In the ED, COVID-19 antigen positive, influenza negative.
This spontaneous report as received from a nurse refers to a 6 month old patient of an unknown gender. On 05-FEB-2015, the patient was vaccinated with improperly stored, oral, ROTATEQ (either lot # K007247 and expiry date: 17-MAR-2016 or lot# K006805 and expiry date: 24-MAR-2016). No adverse events were reported. No product quality complaint (PQC) was reported for ROTATEQ. This is one of the several reports from the same reporter. Additional information has been requested.
Red spot about 5" diameter at injection site. No pain nor itchiness. Discoloration only.
Short seizure, approximately 10 seconds, not associated with fever occurred 24 hours following simultaneous immunization with Hepatitis A #1 and PROQUAD (MMR-Varicella), vaccinated 1/28/13, seizure on 1/29/13. Described as irritability/crying followed by stiffening of body x 10 sec. lateral eye movements followed by blank stare, 30 minute post-ictal period.
Fever; Chills while sleeping; Severe headache; Body aches; This case was reported by a consumer and described the occurrence of fever in a 50-year-old male patient who received Herpes zoster (Shingrix) (batch number 75AX2, expiry date unknown) for prophylaxis.   On 22nd August 2021, the patient received the 1st dose of Shingrix .5 ml. In August 2021, less than a week after receiving Shingrix, the patient experienced fever, chills and general body pain. On 22nd August 2021, the patient experienced headache. On an unknown date, the outcome of the fever, chills, headache and general body pain were recovered/resolved.   The reporter considered the fever, chills, headache and general body pain to be related to Shingrix.  Additional details provided were as follows: The case was reported by patient himself. The patient experienced fever, chills at night while sleeping, severe headache (starting approximately 8 hours after dose and lasted for roughly 24 hours) and body aches. The patient was not hospitalized. All symptoms were gone after 48 hours. Reporter consented to follow-up.
pain in my shoulders; pain goes from one shoulder to the other; Problem sleeping;  trouble sleeping at time; Bursitis; This is spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number was not reported, Expiry date: unknown), via an unspecified route of administration as dose 2, single on an unspecified date in Mar2021 for COVID-19 immunization. Medical history and concomitant medications were not reported. Historical vaccine includes first dose of BNT162B2 via an unspecified route of administration as dose 1, single on an unspecified date in Feb2021 for COVID-19 immunization. The patient reported, in Mar2021 right away the patient had pain in shoulders and was unable to lift arm, over the head and the pain goes from one shoulder to the other. Problem sleeping and went to the doctor. They said they didn't think it was related to the vaccine and then they did prescribed Ibuprofen (Intent: Treatment) and so the patient had Bursitis so but now it is 5 months later and still had. The patient could not lift arm over the head without pain and had trouble sleeping at time and did not want to just keep taking medications. Before the shot the patient never had anything like this. The patient had continued pain in shoulders after the vaccine. Outcome of events was Not recovered/Not resolved.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Extreme fatigue; Nausea; This is a spontaneous report from a contactable consumer. A 71-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 05Mar2021 (at the age of 71-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 11Feb2021 (at the age of 71-years-old) as a single dose for COVID-19 immunisation. On 07Mar2021, the patient experienced extreme fatigue and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event extreme fatigue and nausea was recovered on an unknown date in Mar2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
right knee pain; he experienced bilateral shoulder pain; Parkinson-Turner Syndrome; acute pain; weakness; fatigue; Initial information received on 01-Feb-2023 regarding an unsolicited valid serious case received from a consumer.  This case involves a 63 years old male patient who experienced right knee pain, he experienced bilateral shoulder pain, parkinson-turner syndrome, acute pain, weakness and fatigue after receiving vaccine Influenza Quadrivalent Recombinant Vaccine [Flublok].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included Interferon Alfa (Interferon Alfa).  On an unknown date, the patient received 0.5 ml 1x dose of suspect Influenza Quadrivalent recombinant vaccine (strength, lot number and expiry date: not reported) via intramuscular route in the right deltoid as Immunization.  On 03-Nov-2022, the patient developed a serious right knee pain (arthralgia), bilateral shoulder pain (arthralgia), parkinson-turner syndrome (turner's syndrome), acute pain (pain), weakness (asthenia) and fatigue (unknown latency) following the administration of Influenza Quadrivalent Recombinant Vaccine. This event was assessed as medically significant.  No lab data was reported.  Action taken: Not applicable.  It was not reported if the patient received a corrective treatment for the events.  At time of reporting, the outcome was Recovered / Resolved on an unknown date for the event right knee pain and was Not Recovered / Not Resolved for rest of the events.; Sender's Comments: Sanofi company comment dated 01-Feb-2023: This case involves a 63 years old male patient who experienced right knee pain, he experienced bilateral shoulder pain, parkinson-turner syndrome, acute pain, weakness and fatigue after receiving vaccine Influenza Quadrivalent Recombinant Vaccine [Flublok]. The time to onset was compatible with the role of vaccine. The clinical course of the event was not provided. Furthermore, information regarding condition at the time of vaccination, role of medical history, lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of the suspect vaccine cannot be assessed.
This case was reported by a nurse and described the occurrence of expired vaccine used in a 16-year-old patient who received HAVRIX 1440. On an unknown date, the patient received HAVRIX 1440 at an unknown dose. On an unknown date, an unknown time after receiving HAVRIX 1440, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown. Additional details provided: This was 1 of the 2 cases received from the same reporter.
sore arm; red patch; pink; tender; nausea; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (sore arm), ERYTHEMA (red patch), SKIN DISCOLOURATION (pink), TENDERNESS (tender) and NAUSEA (nausea) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 020N20A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Feb-2021, the patient experienced NAUSEA (nausea). On 27-Feb-2021, the patient experienced PAIN IN EXTREMITY (sore arm), ERYTHEMA (red patch), SKIN DISCOLOURATION (pink) and TENDERNESS (tender). At the time of the report, PAIN IN EXTREMITY (sore arm), ERYTHEMA (red patch), SKIN DISCOLOURATION (pink), TENDERNESS (tender) and NAUSEA (nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided. No relevant concomitant medications reported.
Urticarial and papular eruption of neck and extremities. Itchy, reddish blister at vaccination site. Several bouts of watery diarrhea, dull headache.
Right frontal CVA with left facial droop and LUE weakness. Hospital admission within 6 weeks of receiving the COVID vaccine.
8-11-12 Received shingles vaccine. 8-18-12 Developed shingles. Healthy adult male.
This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant therapies were not reported. On unknown dates the patients were vaccinated with improperly stored ZOSTAVAX (lot # was reported as M005727, expiration date was reported as 03-MAY-2017, route and dose were not reported). The vaccines were exposed to 6 F for 5 minutes without previous excursion. The issue was due to data logger. No symptoms were reported This is one of the several reports from the same reporter. Additional information has been requested.
Case number PHHY2011US40066 is a combined initial and follow-up spontaneous report received from a consumer (patient) respectively on 10 May 2011 and 11 May 2011. This report concerns a 50 old male patient. He had a medical history of arthritis and had no vaccination history with INFLUENZA vaccine. He was vaccinated with S-OIV FLUVIRIN (batch number: unknown) intramuscularly on 02 Jan 2010. Two weeks after vaccination the patient presented with lot of fatigue and weakness ("had no energy"). He also had numbness ("very little feeling") in his hands and feet, double vision which all seemed like a neurological problem. However, a final diagnosis was not made. He was treated with medications (unspecified names) which did not help. The outcome was not reported. The events were reported as severe.
Rash/hives on abdomen 6-8 after injection. Each day, it has spread. Currently, 5 days post injection, the rash/hives is on more of abdomens, lower back, chest, back of neck, and right cheek.
Site: Swelling at Injection Site-Mild, Additional Details: almost immediately after immunizazition   pt arm swelled below injection site   no pain just swelling  no other symptoms\r\ncalled pt at end of shift  still had some swelling and discomfort   ice and some ibuprofen  pt will call md if no change
Office manager calling to report a temperature excursion involving VARlVAX. Caller, "some of the vaccines were administered."; No other AE reported.; This spontaneous report was received from a office manager concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.  On an unknown date, the patient was vaccinated with an improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) 0.5 milliliter, for prophylaxis (lot # T010311 has been verified to be a valid lot number varicella virus vaccine live (oka/merck), expiration date reported and establish as 24-MAR-2022) (strength, route of administration and anatomical location were not provided).  The temperature of storage and time frame of the excursion were -9.51° Celsius (C) for 56 minutes respectively.  A digital data logger was involved, and there was not previous temperature excursion.
Swelling of tongue 30 minutes after vaccination given, urgent care gave short course of steriods and swelling resolved.
Waiting to receive second dose of the vaccine as partially vaccinated; A 17 year old received 1st dose of the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A 17 year old received 1st dose of the vaccine) and PRODUCT DOSE OMISSION ISSUE (Waiting to receive second dose of the vaccine as partially vaccinated) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Feb-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A 17 year old received 1st dose of the vaccine). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Waiting to receive second dose of the vaccine as partially vaccinated). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A 17 year old received 1st dose of the vaccine) and PRODUCT DOSE OMISSION ISSUE (Waiting to receive second dose of the vaccine as partially vaccinated) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported  No treatment medication was reported In the follow up it was reported that patient was partially vaccinated and not experienced any severe adverse reaction.   Most recent FOLLOW-UP information incorporated above includes: On 06-Jun-2021: Partial vaccination event  reported; Sender's Comments: This report refers to a case of product administered to patient of inappropriate age (17 year old) for mRNA-1273 (lot number 015M20A) with no associated AEs reported.
Very bad headache, swollen throat and neck, inflamed sinus cavity, puffy eye lids, very red eyes and a discharge, matted eyelashes this morning, eyes sensitive to bright light, need to lay down and sleep.  Felt bad for about 2 days.
I took aspirin, tylenol  and I ate soup, took 2 days off from work to rest. Vision got blurry Upset stomach Left arm in pain Ever since I took the shot I've been tired.
Complete numbness from waist down. Motor function still normal, but all sensory function gone. Has been diagnosed as transverse myelitis. Have gone through one round of high-dose IV methylprednisolone for 5 days. Currently only have partial recovery.
Rash appeared after first shot on January 18 in my groin area and then again after second shot on February 8, 2021.  Rash disappeared by March 15. It reappeared as hives on April 7. New hives would appear each morning with severe itching. Over time they would go through 4 states - bright pink and itch, splotchy red, red, and then bruise. I was diagnosed with urticarial vasculitis on April 23 by a dermatologist and now I have seen a rheumatologist that confirms it.  I am on steroids to suppress the hives that can cause damage to my blood vessels and organs.  I am on Plaquenil for at least a year and Dapsone.
Two days after injection was given, a red welt measuring approx 4 inches long & 2 inches wide appeared on my upper arm where the injection was given.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication list was not provided. It was reported that the data logger that caller was unable to download were for the months of Dec-2021, Jan-2022, and Feb-2022. The reporter also stated that no adverse reactions were reported by any patients. The reporter reiterated that because her facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. Treatment information was not provided.
Initial unsolicited case received from a nurse on 08 May 2017. This case involves five-year-old female patient who was vaccinated with third dose of DAPTACEL (Batch number: C5014BA, Expiry date: 29 Jul 2018, dose was not reported) intramuscularly in the left deltoid on 29 Nov 2016. The patient illness at the time of vaccination and Pre-existing physician diagnosed allergies, birth defects, medical conditions were unknown. Concomitant medications were not reported. On 30 Nov 2016, 1 day after the vaccination, the patient developed seizure and a fever with a 5 cm red area at injection site on left deltoid, it was also reported that the patient did not go to doctor or ER. The patient was previously vaccinated with two doses of DAPTACEL (batch number, expiry date, dose, route and site of administration was not reported) on an unknown dates. The patient relevant lab tests and corrective treatment were not reported. The outcome of the events were reported as not recovered. Upon internal review the company decided to consider the case as serious due to important medical event Seizure. List of documents held by sender: none. Sender's Comments: This case concerns 5 year old female patient who received DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE and on next day developed seizure, fever and vaccination site erythema. Time to onset is compatible with role of vaccine. However, this case is poorly documented and further information regarding etiological work up, concurrent condition at the time of vaccination, concomitant medication, and investigation results to rule out the alternative cause are needed for a complete assessment of the case.
Diarrhea. A nsg practitioner reported that an infant received her 2nd Prevnar on 10/18/00. Medical history includes sickness. On 10/23/00, the infant developed diarrhea for 4 days. She recovered.
She got a sore arm; 1st dose on March 2020  hasn't gotten her 2nd; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   In March 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced pain in arm and incomplete course of vaccination. On an unknown date, the outcome of the pain in arm was recovered/resolved and the outcome of the incomplete course of vaccination was unknown.   The reporter considered the pain in arm to be related to Shingrix.     Additional Information: GSK Receipt Date: 10-May-2022 Reporter's Comments: The reporter was the patient stating that she got her first shingrix vaccine March 2020, but had not gotten her second. The patient had plan on getting the second vaccine. She also stated that she got a sore arm from the injection that lasted several days. The reporter did not consent to follow-up.  Additional Supportive Information: Till the time of reporting the patient did not received 2nd dose which led to incomplete course of vaccination.
On Saturday, September 18, 2021 client came to vaccination POD for his first Covid-19 Pfizer dose. Client stated to  staff during check-in process that he was vaccinated with Cansino Covid-19 vaccine four months ago without proof of vaccination. At this time Cansino Covid-19 vaccine is not a vaccine approved by the WHO. Elevated to Medical team who approved client to get the Pfizer vaccine as it has been more than 28 days since receiving the one dose of  non-FDA-authorized Covid-19 Cansino vaccine. Client has no history of allergies or previous adverse reactions to other vaccines. Client was to be a 15 minute wait in the Observation Area. Client received his first dose of Covid-19 Pfizer dose (LOT #: FF8839) at approximately 11:30am in his left arm. Client experienced no adverse reaction while waiting in Observation Area and left vaccination site with a steady gait at 11:55 am.
LOCAL REACTION TO L DELTOID: EDEMATOUS, ERYTHEMATOUS, PRURITIS WITH TENDERNESS & WARMTH TO TOUCH X 7 DAYS. NO LAD, AFEBRILE, DECREASED ROM SEC. TO PAIN, NEURO IS INTACT. RA SIZE:23MM, LA-36MM. GIVEN BENADRYL PO Q6H, MOTRIN 800 MG  TID, WARM COMPRESS APPLY TO THE AREA.